Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches

Table 4 Comparative analytical resulted data from simultaneous determination of BUD and AZL in their laboratory synthetic mixture and laboratory prepared dosage form by the proposed HPLC and spectrophotometry methods

HPLC method
	Parameter	Laboratory synthetic mixture			Laboratory prepared dosage form
	Parameter	Proposed method		Comparison method [13, 40]		Proposed method		Comparison method [13, 40]
BUD + AZL	\(\overline{\text{X}}\) ± SD	BUD	99.52 ± 0.21	99.3 ± 0.58	Rhino aqua and Zalastin	BUD	99.39 ± 0.24	100.30 ± 0.87
	\(\overline{\text{X}}\) ± SD	AZL	99.85 ± 0.23	99.59 ± 0.61		AZL	100.10 ± 0.67	99.97 ± 0.42
	t-value	BUD	0.62 (2.13)			BUD	1.75 (2.13)
	t-value	AZL	0.7 (2.13)			AZL	0.29 (2.13)
	F-value	BUD	7. 16 (19.0)			BUD	12.61 (19.0)
	F-value	AZL	6.9 (19.0)			AZL	2.62 (19.0)

Spectrophotometric methods
		Laboratory synthetic mixture			Laboratory prepared dosage form
		BUD		AZL		BUD		AZL
		¹D₂₆₅	¹DD₂₇₀	⁰D₂₉₀		¹D₂₆₅	¹DD₂₇₀	⁰D₂₉₀
BUD + AZL	\(\overline{\text{X}}\) ± SD	99.87 ± 0.37	100.03 ± 0.26	99.88 ± 0.25	Rhino aqua and Zalastin	99.86 ± 0.46	100.12 ± 0.52	99.93 ± 0.19

ISSN: 2661-801X